AR080494A1 - Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienen - Google Patents
Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienenInfo
- Publication number
- AR080494A1 AR080494A1 ARP110100762A ARP110100762A AR080494A1 AR 080494 A1 AR080494 A1 AR 080494A1 AR P110100762 A ARP110100762 A AR P110100762A AR P110100762 A ARP110100762 A AR P110100762A AR 080494 A1 AR080494 A1 AR 080494A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- 2thite
- ppm
- degrees
- crystalline
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 7
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 239000004381 Choline salt Substances 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Una sal cristalina de trometamina caracterizada porque es la sal del compuesto de la siguiente formula (1). Reivindicacion 4: La sal cristalina segun la reivindicacion 1, caracterizada porque tiene un modelo de difraccion de rayos X en polvo que comprende un pico a 5,9 grados 2thita (+- 0,2 grados 2thita) cuando se mide utilizando radiacion CuKalfa y un espectro 13C NMR en estado solido que comprende picos en desplazamientos químicos de 178,3, 138,1 y 27,1 ppm (+- 0,2 ppm). Reivindicacion 5: Una sal cristalina de colina, caracterizada porque es la sal del compuesto de la siguiente formula (1). Reivindicacion 8: La sal cristalina segun la reivindicacion 5, caracterizada porque tiene un modelo de difraccion de rayos X en polvo que comprende un pico a 7,5 grados 2thita (+- 0,2 grados 2thita) cuando se mide utilizando radiacion CuKalfa y un espectro 13C NMR en estado solido que comprende picos en desplazamientos químicos de 175,1, 137,6 y 27,2 ppm (+- 0,2 ppm). Reivindicacion 9: Una sal cristalina de N-metil-D-glucamina, caracterizada porque es la sal del compuesto de la siguiente formula (1). Reivindicacion 12: La sal cristalina segun la reivindicacion 9, caracterizada porque tiene un modelo de difraccion de rayos X en polvo que comprende un pico a 4,4 grados 2thita (+- 0,2 grados 2thita) cuando se mide utilizando radiacion CuKalfa y un espectro 13C NMR en estado solido que comprende picos en desplazamientos químicos de 178,4, 138,0 y 27,0 ppm (+- 0,2 ppm).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31279110P | 2010-03-11 | 2010-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080494A1 true AR080494A1 (es) | 2012-04-11 |
Family
ID=43778392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100762A AR080494A1 (es) | 2010-03-11 | 2011-03-10 | Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienen |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8530497B2 (es) |
| EP (1) | EP2545049B1 (es) |
| JP (2) | JP5687291B2 (es) |
| KR (1) | KR101756632B1 (es) |
| CN (2) | CN102844315B (es) |
| AR (1) | AR080494A1 (es) |
| AU (1) | AU2011224311B2 (es) |
| BR (1) | BR112012022812A2 (es) |
| CA (1) | CA2792684C (es) |
| CL (1) | CL2012002362A1 (es) |
| EA (1) | EA021805B1 (es) |
| IL (1) | IL221198A (es) |
| MX (1) | MX2012009964A (es) |
| NZ (1) | NZ601563A (es) |
| PH (1) | PH12012501805A1 (es) |
| TW (1) | TW201200511A (es) |
| UY (1) | UY33270A (es) |
| WO (1) | WO2011112761A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2331538E (pt) * | 2008-09-16 | 2014-05-12 | Boehringer Ingelheim Int | Sal de sódio de um inibidor de hcv potente |
| KR20110054003A (ko) | 2008-09-17 | 2011-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물 |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| SE1450019A1 (sv) | 2011-10-21 | 2014-01-10 | Abbvie Inc | Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| AU2014233390B2 (en) | 2013-03-15 | 2018-03-01 | Gilead Sciences, Inc. | Macrocyclic and bicyclic inhibitors of hepatitis C virus |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS |
| AU2017364349A1 (en) * | 2016-11-28 | 2019-07-11 | Sarin PARAYIL | Novel organic crystalline salt of haloacetic acid |
| WO2024237331A1 (ja) * | 2023-05-17 | 2024-11-21 | オンコリスバイオファーマ株式会社 | フェナントリジノン誘導体のコリン塩 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0649651B1 (en) | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| ES2297424T3 (es) * | 2003-05-21 | 2008-05-01 | Boehringer Ingelheim International Gmbh | Compuestos inhibidores de la hepatitis c. |
| US7514557B2 (en) | 2004-05-25 | 2009-04-07 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic HCV protease inhibitors |
| PT2331538E (pt) | 2008-09-16 | 2014-05-12 | Boehringer Ingelheim Int | Sal de sódio de um inibidor de hcv potente |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2011
- 2011-03-09 US US13/044,027 patent/US8530497B2/en active Active
- 2011-03-10 CN CN201180011223.2A patent/CN102844315B/zh not_active Expired - Fee Related
- 2011-03-10 WO PCT/US2011/027807 patent/WO2011112761A1/en not_active Ceased
- 2011-03-10 BR BR112012022812A patent/BR112012022812A2/pt not_active Application Discontinuation
- 2011-03-10 EA EA201201277A patent/EA021805B1/ru not_active IP Right Cessation
- 2011-03-10 AU AU2011224311A patent/AU2011224311B2/en not_active Ceased
- 2011-03-10 TW TW100108159A patent/TW201200511A/zh unknown
- 2011-03-10 AR ARP110100762A patent/AR080494A1/es unknown
- 2011-03-10 CN CN201510227989.4A patent/CN104945396B/zh not_active Expired - Fee Related
- 2011-03-10 NZ NZ601563A patent/NZ601563A/en not_active IP Right Cessation
- 2011-03-10 KR KR1020127023651A patent/KR101756632B1/ko not_active Expired - Fee Related
- 2011-03-10 MX MX2012009964A patent/MX2012009964A/es active IP Right Grant
- 2011-03-10 JP JP2012557229A patent/JP5687291B2/ja not_active Expired - Fee Related
- 2011-03-10 UY UY0001033270A patent/UY33270A/es not_active Application Discontinuation
- 2011-03-10 CA CA2792684A patent/CA2792684C/en not_active Expired - Fee Related
- 2011-03-10 PH PH1/2012/501805A patent/PH12012501805A1/en unknown
- 2011-03-10 EP EP11708380.8A patent/EP2545049B1/en not_active Not-in-force
-
2012
- 2012-07-31 IL IL221198A patent/IL221198A/en active IP Right Grant
- 2012-08-24 CL CL2012002362A patent/CL2012002362A1/es unknown
-
2013
- 2013-07-30 US US13/954,404 patent/US20130317061A1/en not_active Abandoned
-
2015
- 2015-01-21 JP JP2015009113A patent/JP2015143223A/ja active Pending
- 2015-02-13 US US14/621,534 patent/US9382240B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102844315A (zh) | 2012-12-26 |
| JP2013522221A (ja) | 2013-06-13 |
| PH12012501805A1 (en) | 2022-10-05 |
| JP2015143223A (ja) | 2015-08-06 |
| KR20130009966A (ko) | 2013-01-24 |
| IL221198A0 (en) | 2012-10-31 |
| EP2545049A1 (en) | 2013-01-16 |
| TW201200511A (en) | 2012-01-01 |
| CL2012002362A1 (es) | 2013-01-11 |
| CA2792684A1 (en) | 2011-09-15 |
| CN104945396A (zh) | 2015-09-30 |
| NZ601563A (en) | 2013-12-20 |
| WO2011112761A1 (en) | 2011-09-15 |
| US9382240B2 (en) | 2016-07-05 |
| US20150166530A1 (en) | 2015-06-18 |
| US20130317061A1 (en) | 2013-11-28 |
| CN102844315B (zh) | 2015-05-20 |
| MX2012009964A (es) | 2012-09-21 |
| EP2545049B1 (en) | 2015-10-14 |
| UY33270A (es) | 2011-10-31 |
| EA021805B1 (ru) | 2015-09-30 |
| US20120059033A1 (en) | 2012-03-08 |
| CN104945396B (zh) | 2018-02-27 |
| EA201201277A1 (ru) | 2013-04-30 |
| CA2792684C (en) | 2018-07-31 |
| AU2011224311B2 (en) | 2014-08-14 |
| JP5687291B2 (ja) | 2015-03-18 |
| KR101756632B1 (ko) | 2017-07-11 |
| IL221198A (en) | 2017-01-31 |
| BR112012022812A2 (pt) | 2018-05-15 |
| AU2011224311A1 (en) | 2012-08-23 |
| US8530497B2 (en) | 2013-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080494A1 (es) | Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienen | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
| FI3351539T3 (fi) | Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä | |
| AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
| CA2875877C (en) | Syk inhibitors | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| PE20140420A1 (es) | Forma cristalina de un inhibidor de la interaccion de mdm2/4 y p53 | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| UA116923C2 (uk) | (6S,9aS)-N-БЕНЗИЛ-6-[(4-ГІДРОКСИФЕНІЛ)МЕТИЛ]-4,7-ДІОКСО-8-({6-[3-(ПІПЕРАЗИН-1-ІЛ)АЗЕТИДИН-1-ІЛ]ПІРИДИН-2-ІЛ}МЕТИЛ)-2-(ПРОП-2-ЕН-1-ІЛ)-ОКТАГІДРО-1H-ПІРАЗИНО[2,1-c][1,2,4]ТРИАЗИН-1-КАРБОКСАМІДНА СПОЛУКА | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| JP2013541600A5 (es) | ||
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| MX343540B (es) | Compuesto de tiazol y metodo de preparacion y uso del mismo. | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| UY33299A (es) | Derivados de 6-(alquil-o cicloalquil-triazolopiridacina-silfanil)benzotiazoles:preparacion, aplicación como medicamentos y utilizacion como inhibidores de la met | |
| AR089631A1 (es) | FORMA CRISTALINA d DE LA SAL DE ARGININA DE PERINDOPRILO, SU PROCEDIMIENTO DE PREPARACION, Y LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
| AR083256A1 (es) | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico | |
| ES2489467T3 (es) | Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico | |
| ECSP12012207A (es) | Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |